Advertisement

CEN Case Reports

, Volume 7, Issue 1, pp 132–136 | Cite as

Advanced native-kidney carcinoma in a heart- and kidney-transplanted patient: a case report

  • Matteo Paoletti
  • Barbara Cattadori
  • Marilena Gregorini
  • Alessandra Viglio
  • Giovanni Gentile
  • Andrea Maria D’Armini
  • Carlo Pellegrini
  • Alfredo La Fianza
Case Report
  • 53 Downloads

Abstract

Malignancies are one of the leading causes of death in long-term surviving transplant recipients. Dose and prolonged durations of immunosuppressive regimens are considered the main cause, through a direct oncogenic effect and a renowned interaction on physiological anti-viral and anti-oncogenic immune response. Specific neoplasms are known to occur with different frequencies according to the transplanted organ. As a consequence, imaging screenings have been implemented in many graft surveillance programs, although a wide consensus on the timing and modality has not been concurred. There are little data available in the literature regarding incidence of de-novo malignancies in multi-organ recipients. We report the case of a 66-year-old man who developed a renal mass 10 years after a combined heart–kidney transplant.

Keywords

Cancer screening Immunosuppression Kidney transplantation Heart transplantation Post-transplant malignancy 

Notes

Compliance with ethical standards

Conflict of interest

All the authors have declared no competing interests.

Human participants and animal rights statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from the patient included in this article.

References

  1. 1.
    Tsai H, Lee C, Kuo C, et al. De novo malignancy in organ transplant recipients in Taiwan : a nationwide cohort population study. Oncotarget. 2017;8(22):36685–95.Google Scholar
  2. 2.
    Domhan S, Zeier M, Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transpl. 2009;24:1097–103.CrossRefGoogle Scholar
  3. 3.
    Agraharkar ML, Cinclair RD, Kuo Y-F, et al. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2017;66:383–9.  https://doi.org/10.1111/j.1523-1755.2004.00741.x.CrossRefGoogle Scholar
  4. 4.
    Morris PJ. Transplantation–a medical miracle of the 20th century. N Engl J Med. 2004;351:2678–80.  https://doi.org/10.1056/NEJMp048256.CrossRefPubMedGoogle Scholar
  5. 5.
    Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3:1–15.  https://doi.org/10.1101/cshperspect.a015677.CrossRefGoogle Scholar
  6. 6.
    Campistol JM. Minimizing the risk of posttransplant malignancy. Transpl Proc. 2008;40:27–30.  https://doi.org/10.1016/j.transproceed.2008.10.015.CrossRefGoogle Scholar
  7. 7.
    Webster AC, Craig JC, Simpson JM, et al. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15 183 recipients. Am J Transpl. 2007;7:2140–51.  https://doi.org/10.1111/j.1600-6143.2007.01908.x.CrossRefGoogle Scholar
  8. 8.
    Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. Jama. 2011;306:1891–901.  https://doi.org/10.1001/jama.2011.1592.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Castello M, Gregorini M, Rampino T, et al. A retrospective analysis of dermatological lesions in kidney transplant patients. Indian J Med Res. 2013;137:1188–92.PubMedPubMedCentralGoogle Scholar
  10. 10.
    AlBugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transpl Rev. 2014;28:76–83.  https://doi.org/10.1016/j.trre.2013.12.002.CrossRefGoogle Scholar
  11. 11.
    Végsö G, Toronyi É, Hajdu M, et al. Renal cell carcinoma of the native kidney: a frequent tumor after kidney transplantation with favorable prognosis in case of early diagnosis. Transpl Proc. 2011;43:1261–3.  https://doi.org/10.1016/j.transproceed.2011.03.068.CrossRefGoogle Scholar
  12. 12.
    Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M. EAU guidelines on renal transplantation. Eur Urol. 2005;47(2):156–66.Google Scholar
  13. 13.
    Frascà GM, Sandrini S, Cosmai L, et al. Renal cancer in kidney transplanted patients. J Nephrol. 2015;28:659–68.  https://doi.org/10.1007/s40620-015-0219-8.CrossRefPubMedGoogle Scholar
  14. 14.
    Kellerman L, Neugut A, Burke B, Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol. 2009;103:562–6.  https://doi.org/10.1016/j.amjcard.2008.10.026.CrossRefPubMedGoogle Scholar
  15. 15.
    Sánchez-Lázaro IJ, Almenar-Bonet L, Martínez-Dolz L, et al. Post-heart transplant tumors: chronology and impact on survival. Transpl Proc. 2010;42:3201–3.  https://doi.org/10.1016/j.transproceed.2010.05.052.CrossRefGoogle Scholar
  16. 16.
    Almenar-Bonet L. Spanish heart transplantation registry. 18th official report of the Spanish society of cardiology working group on heart failure, heart transplantation and associated therapies (1984–2006). Rev Española Cardiol (English Ed). 2007;60:1177–87.Google Scholar
  17. 17.
    Roussel JC, Baron O, Périgaud C, et al. Outcome of heart transplants 15–20 years ago: graft survival, post-transplant morbidity, and risk factors for mortality. J Heart Lung Transpl. 2008;27:486–93.  https://doi.org/10.1016/j.healun.2008.01.019.CrossRefGoogle Scholar
  18. 18.
    Lateef N, Basit KA, Abbasi N, et al. Malignancies after heart transplant. Exp Clin Transpl. 2016;14:12–6.  https://doi.org/10.6002/ect.2015.0214.Google Scholar
  19. 19.
    Anthony C, Jabbour A, Kotlyar E, et al. A 25 year review of combined cardiac and renal transplant outcomes in patients with end stage cardiac failure on renal replacement therapy. A single center experience. J Heart Cardiol. 2016;2:1–9.  https://doi.org/10.15436/2378-6914.16.021.Google Scholar
  20. 20.
    Bacchi G, Potena L, Mosconi G, et al. Combined heart-kidney transplantation: a single center experience. Open J Organ Transpl Surg. 2011;1:14–8.  https://doi.org/10.4236/ojots.2011.12003.CrossRefGoogle Scholar
  21. 21.
    Awad M, Czer LSC, Esmailian F, et al. Combined heart and kidney transplantation: a 23-year experience. Transpl Proc. 2017;49:348–53.  https://doi.org/10.1016/j.transproceed.2016.11.040.CrossRefGoogle Scholar
  22. 22.
    López-Sainz A, Barge-Caballero E, Paniagua-Martin MJ, et al. Clinical characteristics and long-term outcomes of patients undergoing combined heart-kidney transplantation: a single-center experience. Transpl Proc. 2015;47:123–6.  https://doi.org/10.1016/j.transproceed.2014.11.009.CrossRefGoogle Scholar
  23. 23.
    Vermes E, Grimbert P, Sebbag L, et al. Long-term results of combined heart and kidney transplantation: a French multicenter study. J Heart Lung Transpl. 2009;28:440–5.  https://doi.org/10.1016/j.healun.2009.01.020.CrossRefGoogle Scholar
  24. 24.
    Hevia V, Gomez V, Diez Nicolas V, et al. Development of urologic de novo malignancies after renal transplantation. Transpl Proc. 2014;46:170–5.  https://doi.org/10.1016/j.transproceed.2013.12.004.CrossRefGoogle Scholar
  25. 25.
    Sun IO, Ko YM, Kim EY, et al. Clinical characteristics and outcomes in renal transplant recipients with renal cell carcinoma in the native kidney. Korean J Intern Med. 2013;28:347–51.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kato T, Kakuta Y, Abe T, et al. The benefits of cancer screening in kidney transplant recipients: a single-center experience. Cancer Med. 2016;5:153–8.  https://doi.org/10.1002/cam4.568.CrossRefPubMedGoogle Scholar
  27. 27.
    La Fianza A, Pellegrini C, Berton F, et al. Diagnostic imaging of lung cancer after heart transplantation. Tumori. 2006;92:429–32.PubMedGoogle Scholar
  28. 28.
    Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transpl. 2011;11:86–92.  https://doi.org/10.1111/j.1600-6143.2010.03303.x.CrossRefGoogle Scholar
  29. 29.
    Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transpl 2009, 9(Suppl 3), pp. S1–155. https://doi.org/10.1111/j.1600-6143.2009.02834.x.
  30. 30.
    Ambrosi P, Bertucci F, Kreitmann B. High incidence of asymptomatic renal cancer in late survivors after heart transplantation. J Heart Lung Transpl. 2011;30:1202–3.  https://doi.org/10.1016/j.healun.2011.05.003.CrossRefGoogle Scholar
  31. 31.
    Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102:605–13.  https://doi.org/10.1093/jnci/djq099.CrossRefPubMedGoogle Scholar
  32. 32.
    Acuna SA, Fernandes KA, Daly C, et al. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncol. 2016;2:1–8.  https://doi.org/10.1001/jamaoncol.2015.5137.CrossRefGoogle Scholar
  33. 33.
    European Best Practice Guidelines for Renal Transplantation. Section IV.1 Organization of follow-up of transplant recipients after the first year. Nephrol Dial Transplant. 2002;17(Suppl 4):3–4.  https://doi.org/10.1093/ndt/17.suppl_4.3-a.Google Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Matteo Paoletti
    • 1
  • Barbara Cattadori
    • 2
  • Marilena Gregorini
    • 3
  • Alessandra Viglio
    • 4
  • Giovanni Gentile
    • 1
  • Andrea Maria D’Armini
    • 2
    • 5
    • 6
  • Carlo Pellegrini
    • 2
    • 5
    • 6
  • Alfredo La Fianza
    • 1
  1. 1.Institute of RadiologyIRCCS Policlinico San Matteo, University of PaviaPaviaItaly
  2. 2.Department of Cardiac SurgeryIRCCS Policlinico San MatteoPaviaItaly
  3. 3.Nephrology, Dialysis and Transplant UnitIRCCS Policlinico San Matteo, University of PaviaPaviaItaly
  4. 4.Department of PathologyIRCCS Policlinico San Matteo; University of PaviaPaviaItaly
  5. 5.School of “Cardiovascular Pathophysiology, Cardiac Perfusion”University of PaviaPaviaItaly
  6. 6.Chair of Cardiac SurgeryUniversity of PaviaPaviaItaly

Personalised recommendations